Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Glucotrack (GCTK) Research & Development (2016 - 2020)

Glucotrack's Research & Development history spans 7 years, with the latest figure at $264000.0 for Q4 2020.

  • For the quarter ending Q4 2020, Research & Development fell 34.39% year-over-year to $264000.0, compared with a TTM value of $1.5 million through Dec 2020, down 4.61%, and an annual FY2025 reading of $9.8 million, up 3.31% over the prior year.
  • Research & Development for Q4 2020 was $264000.0 at Glucotrack, down from $476000.0 in the prior quarter.
  • The five-year high for Research & Development was $1.4 million in Q4 2017, with the low at $264000.0 in Q4 2020.
  • Average Research & Development over 5 years is $609477.6, with a median of $580517.0 recorded in 2016.
  • Year-over-year, Research & Development skyrocketed 109.72% in 2017 and then plummeted 66.88% in 2019.
  • Tracing GCTK's Research & Development over 5 years: stood at $654984.0 in 2016, then soared by 109.72% to $1.4 million in 2017, then dropped by 11.57% to $1.2 million in 2018, then plummeted by 66.88% to $402384.0 in 2019, then tumbled by 34.39% to $264000.0 in 2020.
  • Per Business Quant, the three most recent readings for GCTK's Research & Development are $264000.0 (Q4 2020), $476000.0 (Q3 2020), and $379000.0 (Q2 2020).